Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer

Simple item page
dc.contributor.authorSezgin C.
dc.contributor.authorKarabulut B.
dc.contributor.authorUslu R.
dc.contributor.authorSanli U.A.
dc.contributor.authorGoksel G.
dc.contributor.authorZekioglu O.
dc.contributor.authorOzdemir N.
dc.contributor.authorGoker E.
dc.date.accessioned2024-07-22T08:24:05Z
dc.date.available2024-07-22T08:24:05Z
dc.date.issued2005
dc.description.abstractThe authors compare results obtained from weekly paclitaxel treatment in advanced breast cancer patients with biological and clinical prognostic factors. Expression of c-erbB-2, Ki-67, p53 and hormone receptors (HR) was examined by immunohistochemistry in samples of breast tissue from 30 patients. Univariate analysis showed that Ki-67 positivity and low performance status (PS) were associated with poor outcome (P <0.05). We observed that expression of p53 and c-erbB-2 did not have any negative effect on response to chemotherapy and survival. HR-negative patients had better response and slightly statistically significant overall survival (OS) rates compared to HR-positive patients (P >0.05). In a multivariate analysis low PS was the only significant predictor of shorter survival (P <0.05). In conclusion, while the expression of p53 and c-erbB-2 did not have any effect on treatment results, negative Ki-67 expression and negative HR status were associated with better OS in this patient population. PS was the only significant predictor for OS. © E.S.I.F.T. srl - Firenze.
dc.identifier.DOI-ID10.1179/joc.2005.17.1.96
dc.identifier.issn1120009X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19825
dc.language.isoEnglish
dc.publisherE.S.I.F.T. srl
dc.subjectantiestrogen
dc.subjectepidermal growth factor receptor 2
dc.subjecthormone receptor
dc.subjectKi 67 antigen
dc.subjectpaclitaxel
dc.subjectprotein p53
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectaged
dc.subjectanalytic method
dc.subjectanaphylaxis
dc.subjectantigen expression
dc.subjectarticle
dc.subjectblood toxicity
dc.subjectbone metastasis
dc.subjectbreast
dc.subjectbreast cancer
dc.subjectcancer chemotherapy
dc.subjectcancer hormone therapy
dc.subjectcancer patient
dc.subjectcancer survival
dc.subjectclinical article
dc.subjectclinical observation
dc.subjectcontrolled study
dc.subjectdrug response
dc.subjectfatigue
dc.subjectfemale
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunohistochemistry
dc.subjectmultivariate analysis
dc.subjectmyalgia
dc.subjectnausea
dc.subjectneuropathy
dc.subjectonycholysis
dc.subjectoutcomes research
dc.subjectprediction
dc.subjectprognosis
dc.subjectprotein analysis
dc.subjectprotein expression
dc.subjectside effect
dc.subjectstatistical significance
dc.subjectsurvival rate
dc.subjectsurvival time
dc.titlePotential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer
dc.typeArticle

Files

Collections

Scopus Koleksiyonu